Dr. Reshma Ramlal, MD

Dr. Ramlal practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Ramlal's NPI, 1275763989, was assigned on July 16, 2009. Dr. Ramlal graduated from University of the West Indies Faculty of Medicine in 2005. Dr. Ramlal's Kentucky license number on file is 49611.

Dr. Ramlal's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Ramlal's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Ramlal to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ramlal practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Ramlal's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Ramlal is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Ramlal's licenses on file in 3 states: Kentucky, Florida and Missouri.

Dmand AI lists chronic leukemia, lymphoma, multiple myeloma and purpura and thrombocytopenia among the conditions Dr. Ramlal treats.

CMS data shows 136 Medicare services from Dr. Ramlal across 4 procedure codes in 2024, for 79 Medicare patients. Medicare paid $13,682 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 79 Medicare patients who saw Dr. Ramlal in 2024. The largest group is 65 to 74, with 49 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 14% are also on Medicaid. Their average risk score is 3.34, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ramlal's median patient age at 65, with 40% women.

In 2024, Dr. Ramlal wrote 580 Medicare Part D claims for 72 patients. 72% of them were for generic drugs. CMS names the drug for 389 of them, across 18 drugs with 11 or more claims each, at $1,353,612 in total drug cost. In 2023, CMS named 686 claims across 26 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Ramlal for performance year 2024, reported as part of a group. Dr. Ramlal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ramlal as offering telehealth.

Dmand AI links 11 papers to Dr. Ramlal, published from 2017 to 2021. 2017 was the busiest year, with 2. The most frequent topics are Leukemia, Myeloid, Acute, Myelodysplastic Syndromes and Precursor Cell Lymphoblastic Leukemia-Lymphoma. Dr. Ramlal has published most often in Blood. Dr. Ramlal's most frequent co-authors are Gerhard Carl Hildebrandt, MD, Reinhold Munker and Ayman Hisham Yousef Qasrawi, MD.

CMS Open Payments shows 9 general payments to Dr. Ramlal from 5 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 62% of the total. Sanofi and Genzyme US Companies paid the most, $245.

Dmand AI lists 2 awards for Dr. Ramlal, most recently LLS Woman of the Year Award in 2020.

Dr. Ramlal graduated from University of the West Indies Faculty of Medicine in 2005. Dr. Ramlal is a member of ACP, ASCO and ASH.

Dr. Ramlal is in network with 9 carriers, including Aetna, Elevance and Humana. HMO plans come from the most carriers, 5. Check the plan with the practice before a visit.